Uruguay marijuana draws pharmaceuticals' interest: report

January 6, 2014

Foreign pharmaceutical companies have expressed interest in buying marijuana for medical uses from Uruguay, which last month became the world's first country to legalize the cultivation and sale of the drug, local media reported Monday.

The newspaper El Observador said the National Drug Board has been in contact with pharmaceutical laboratories from Israel and Chile, while Canadian businesses have contacted Uruguayan politicians and organizations to present proposals for buying cannabis.

"It is true they have consulted us to set up in Uruguay, which is a great challenge," presidential aide Diego Canepa told the newspaper.

Uruguay became the first country to legalize the cultivation, distribution and sale of marijuana December 24 when President Jose Mujica signed a law creating a government-regulated marketplace for the .

His government is currently drawing up specific rules and regulations that will apply.

The National Drug Board says it expects cannabis to go to market beginning in September.

"While it was not an objective of the law, Uruguay is becoming a biotechnology pole. It's a highly competitive area, but one that is rapidly developing," Canepa said.

"For some time, medicinal was only thought of as an analgesic, but now they are studying whether some derivatives can be used in medications," he said.

Explore further: Uruguay to start selling marijuana next year: official

Related Stories

Uruguay to start selling marijuana next year: official

October 21, 2013
Uruguay is planning to start selling marijuana legally next year, a top official said, though the Senate must still approve the proposed legislation.

Uruguay's lower house approves legal regulated marijuana

August 1, 2013
Uruguay's lower house Wednesday approved a controversial bill which for the first time would put a government in charge of production and distribution of legal marijuana.

Uruguay to approve pot dealing, despite risks

December 9, 2013
Uruguay is pushing ahead to create a legal marijuana market despite warnings from educators, psychiatrists and pharmacists of dangerous side effects.

New York may allow medical marijuana use: report

January 5, 2014
New York is planning to loosen its marijuana laws to allow limited use of the drug by people suffering serious illness, the New York Times reported Saturday, citing state officials.

Czechs award first licence to import medical marijuana

November 19, 2013
The Czech health ministry said Tuesday it had awarded its first licence to import marijuana, months after the European Union member legalised the drug for medical purposes.

Hearings to start in Uruguay anti-smoking suit

February 4, 2013
Uruguay faces its first hearings in the French capital this week in a lawsuit filed by US tobacco giant Philip Morris International against its anti-smoking laws, an official said Monday.

Recommended for you

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

Non-psychotropic cannabinoids show promise for pain relief

September 4, 2017
Some cancers love bone. They thrive in its nutrient-rich environment while gnawing away at the very substrate that sustains them, all the while releasing inflammatory substances that cause pain—pain so severe that opioids ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.